Retatrutide Research Overview:
What the Studies Show
Updated April 2026 · For research use only
Retatrutide (developmental code: LY3437943) has emerged as one of the most extensively studied investigational peptides of the past several years. Developed by Eli Lilly and Company, it has advanced through multiple phases of clinical evaluation and generated a substantial body of peer-reviewed literature examining its pharmacological profile, receptor binding activity, and metabolic effects in human subjects. This post summarizes the publicly available academic and clinical data on Retatrutide for researchers seeking a grounded overview of where the science currently stands.
What is Retatrutide at a Molecular Level?
Retatrutide is a synthetic, single-chain peptide engineered to function as a triple hormone receptor agonist. Its mechanism distinguishes it from earlier-generation incretin-based compounds: where semaglutide targets the GLP-1 receptor alone, and tirzepatide engages both GLP-1 and GIP receptors, Retatrutide simultaneously activates all three of the following G-protein–coupled receptors:
Structurally, Retatrutide is conjugated to a fatty diacid moiety via a linker chain, enabling extended half-life through albumin binding and allowing for once-weekly subcutaneous dosing in trial protocols. This structural feature is analogous to the fatty acid conjugation seen in semaglutide, though the triple-agonist pharmacophore is unique to Retatrutide’s class.
The molecular weight of Retatrutide is approximately 4,862 Da. Research-grade material is supplied in lyophilized or solution form, with amino acid sequencing designed to preserve potency across all three receptor targets. The glucagon receptor agonism component is particularly notable from a research standpoint, as it introduces hepatic metabolic modulation — including increased fatty acid oxidation and thermogenic signalling — that is absent in dual GLP-1/GIP formulations.
Phase 1 and Early Clinical Data
The earliest human data on Retatrutide emerged from a Phase 1b study in participants with type 2 diabetes. At the highest dose assessed (12 mg), the compound produced a placebo-adjusted mean weight reduction of approximately 8.96 kg (~10%) over just 12 weeks — a result that set expectations for subsequent trials and positioned Retatrutide as a compound warranting larger-scale investigation.
Phase 2 Trial: NEJM Publication (2023)
The pivotal Phase 2 data for Retatrutide was published in The New England Journal of Medicine in June 2023, coinciding with a presentation at the American Diabetes Association’s 83rd Scientific Sessions. This multicenter, randomized, double-blind, placebo-controlled trial enrolled 338 participants with obesity or overweight (BMI ≥27 kg/m²) without type 2 diabetes, running from May 2021 through November 2022.
Notably, participants had not reached a weight plateau by study end, suggesting continued reduction was likely with longer exposure. Exploratory cardiometabolic endpoints showed directional improvements in systolic and diastolic blood pressure, triglycerides, LDL-cholesterol, HbA1c, and fasting glucose across treatment arms.
Systematic Review and Meta-Analysis (2024)
A 2024 systematic review and meta-analysis encompassing 878 patients across three randomized controlled trials quantified Retatrutide’s effects across pooled data, drawing from PubMed, Scopus, Web of Science, and Cochrane databases through May 2024. The pooled analysis reported the following mean differences versus placebo:
The authors noted that these pooled results represented remarkably high efficacy relative to other anti-obesity agents studied to that point, and suggested that conventional 5% weight-reduction targets may warrant reassessment in the context of triple-agonist pharmacology. The safety profile was consistent with other incretin-class compounds, with nausea the most frequently reported adverse event, and overall discontinuation rates remaining relatively low.
Liver Fat Research: Nature Medicine (2024)
A Phase 2a substudy published in Nature Medicine in 2024 investigated Retatrutide’s effects in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The prespecified primary endpoint was relative change in liver fat percentage at 24 weeks, measured by DXA.
The data raised mechanistic questions about whether Retatrutide’s GCGR agonism contributes hepatic fat-lowering effects beyond those attributable to weight reduction alone — a finding with implications for future mechanistic research in this area.
Phase 3 TRIUMPH Program
The TRIUMPH Phase 3 program, initiated in 2023, has enrolled more than 5,800 participants across four global registrational trials evaluating Retatrutide in obesity and overweight, obstructive sleep apnea, and knee osteoarthritis, across doses of 2 mg, 4 mg, 6 mg, 9 mg, and 12 mg.
In December 2025, Eli Lilly announced positive topline results from the TRIUMPH-4 trial (445 participants). Using the treatment-regimen estimand, the 12 mg arm recorded a mean body weight reduction of 23.7% (27.2 kg / 60.0 lbs); the 9 mg arm recorded 20.0% (22.9 kg / 50.5 lbs); placebo recorded 4.6%. A separate efficacy estimand analysis at 68 weeks — tracking all participants who remained on study intervention — reported weight loss of 28.7% (12 mg) and 26.4% (9 mg) versus 2.1% for placebo. Secondary endpoint data showed a high proportion of participants achieving ≥25%, ≥30%, and ≥35% weight loss thresholds, described by investigators as rarely observed in prior obesity trials. WOMAC knee pain subscale scores were reduced by up to 4.5 points (75.8%) in the highest-dose arm. Seven additional Phase 3 trials are expected to report results in 2026.
Research Storage and Handling
Proper storage is critical to maintaining the integrity of Retatrutide peptide material. The following guidance reflects standard practices for lyophilized fatty diacid–conjugated peptides of this structural class:
| Condition | Guidance |
| Lyophilized form | Store at −20°C in a dry, light-protected environment. Stability generally maintained for 24 months or longer under these conditions. |
| Reconstituted solution | Store at 4°C in sterile bacteriostatic water or PBS at physiologically relevant pH. Use within 28–30 days. |
| Freeze-thaw cycles | Avoid. Repeated cycling degrades peptide structure and reduces purity. |
| Handling | Aseptic conditions required. Protect from prolonged light exposure. |
| Purity verification | Research-grade material should carry a COA with HPLC purity ≥98% and mass spectrometry confirmation of molecular identity. |
References
Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048.
Systematic review and meta-analysis of randomized controlled trials. PubMed/PMC. 2024 (3 RCTs; n=878).
Eli Lilly and Company. TRIUMPH-4 Phase 3 Topline Results. Press release, December 11, 2025.